



SEMINAR LUNCHEON

Vancouver-Pharmaceutical & BioScience Society

Convertible CAR – Cell Therapy

Event Time: June 11th, 2019

Registration: 11:00am; Networking & Vendor Show: 11:00am-12:00pm; Lunch: 11:30pm; Seminar: 12:00pm-1:00pm

Speaker: **David W. Martin, Jr., M.D.**

Location: The Floral Hall at VanDusen Gardens, Oak St. at 37th Ave, Vancouver. Parking is free.

General Registration: www.PBSS.org

Sponsorship: CDN\$1250 for major sponsorship; CDN\$350 for vendor show.

Fees: \$5.00 seminar-luncheon registration (online until June 7th, 2019);
\$40 on-site registration (cash or cheque only).

About the Seminar:

Dr Martin will discuss progress in the field of Immuno-oncology, including the development of *convertibleCAR*[™]-T cells, at Xyphos Biosciences Inc., which provide a solution to the frequent problems of standard CAR-T technology. *convertibleCAR*[™] technology is based on a unique receptor-antibody control system engineered from protein components of the human NKG2D receptor/MIC ligand immune surveillance pathway. Through minimal mutation of the natural NKG2D receptor and directed evolution of small modular MIC domains that selectively bind the mutated NKG2D, an inert NKG2D CAR (iNKG2DCAR) was created that can only be activated using bispecific MIC-Antibody fusions (MicAbodies). The resulting platform enables a single iNKG2D CAR-T cell therapy to be precisely controlled using a tumor-specific MicAbody, and redirected to any antigen of choice.

About the Speaker:

David W. Martin, Jr., M.D., is Chairman & CSO of Xyphos Biosciences, Inc., a biotechnology company in South San Francisco focused on Immuno-oncology. He co-founded and was CEO of AvidBiotics, the predecessor company of Xyphos; co-founder and CEO of Eos Biotechnology (1996-2003) an oncology focused company. He also served as President of Chiron Therapeutics (1994-1995), and Executive Vice-president of R&D at DuPont Merck (1991-1993). Prior to joining Genentech, where he was Senior Vice-president of R&D (1982-1990), he was Professor of Medicine and of Biochemistry at UCSF and Investigator, Howard Hughes Medical Institute. He attended M.I.T. and received his M.D. from Duke University. He has served as board director of several private and public life science companies, including lead director for more than a decade for both Cubist and Varian Medical Systems. Currently he's a director of Ionetix and a member of the oversight committee of CIRM.

Contact us: Info.vancouver@pbss.org